MedTrace Logo

PiB PET Scanning in Speech and Language Based Dementias

NCT01623284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2015-12-22

No results posted yet for this study

Summary

The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.

Conditions

  • PPA
  • Primary Progressive Aphasia
  • Aphasia
  • Non-fluent Aphasia
  • Semantic Dementia
  • Apraxia of Speech
  • Primary Progressive Nonfluent Aphasia
  • Progressive Aphasia

Interventions

DRUG

C-11 PiB

One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).

DRUG

F-18 FDG

One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).

Sponsors & Collaborators

Principal Investigators

  • Keith A Josephs, M.D. MST, MSc · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623284 on ClinicalTrials.gov